BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Aiura K, Takahashi S, Matsui J, Ueda M, Kitagawa Y. Beneficial effects of 5-Fluorouracil and heparin-based portal infusion chemotherapy combined with mitomycin C and cisplatin after curative resection of pancreatic cancer. Pancreatology. 2010;10:250-258. [PMID: 20484963 DOI: 10.1159/000244265] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Hudson CD, Hagemann T, Mather SJ, Avril N. Resistance to the tyrosine kinase inhibitor axitinib is associated with increased glucose metabolism in pancreatic adenocarcinoma. Cell Death Dis 2014;5:e1160. [PMID: 24722285 DOI: 10.1038/cddis.2014.125] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
2 Nakano Y, Kitago M, Shinoda M, Abe Y, Yagi H, Hibi T, Takeuchi A, Aiura K, Itano O, Kitagawa Y. Clinical predictive factors of long-term survival after curative resection of pancreatic cancer: a retrospective study. Cancer Med 2017;6:2278-86. [PMID: 28925039 DOI: 10.1002/cam4.1178] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
3 Endo Y, Kitago M, Aiura K, Shinoda M, Yagi H, Abe Y, Oshima G, Hori S, Nakano Y, Itano O, Fukada J, Masugi Y, Kitagawa Y. Efficacy and safety of preoperative 5-fluorouracil, cisplatin, and mitomycin C in combination with radiotherapy in patients with resectable and borderline resectable pancreatic cancer: a long-term follow-up study. World J Surg Oncol. 2019;17:145. [PMID: 31420046 DOI: 10.1186/s12957-019-1687-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
4 Nakano Y, Kitago M, Matsuda S, Nakamura Y, Fujita Y, Imai S, Shinoda M, Yagi H, Abe Y, Hibi T, Fujii-Nishimura Y, Takeuchi A, Endo Y, Itano O, Kitagawa Y. KRAS mutations in cell-free DNA from preoperative and postoperative sera as a pancreatic cancer marker: a retrospective study. Br J Cancer. 2018;118:662-669. [PMID: 29360815 DOI: 10.1038/bjc.2017.479] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 9.5] [Reference Citation Analysis]
5 Fujita Y, Kitago M, Masugi Y, Itano O, Shinoda M, Abe Y, Hibi T, Yagi H, Fujii-Nishimura Y, Sakamoto M, Kitagawa Y. Two cases of pancreatic ductal adenocarcinoma with intrapancreatic metastasis. World J Gastroenterol 2016; 22(41): 9222-9228 [PMID: 27895409 DOI: 10.3748/wjg.v22.i41.9222] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
6 Schunke KJ, Rosati LM, Zahurak M, Herman JM, Narang AK, Usach I, Klein AP, Yeo CJ, Korman LT, Hruban RH, Cameron JL, Laheru DA, Abrams RA. Long-term analysis of 2 prospective studies that incorporate mitomycin C into an adjuvant chemoradiation regimen for pancreatic and periampullary cancers. Adv Radiat Oncol 2018;3:42-51. [PMID: 29556579 DOI: 10.1016/j.adro.2017.07.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
7 Nakano Y, Kitago M, Shinoda M, Yagi H, Abe Y, Takano K, Oshima G, Takeuch A, Endo Y, Kitagawa Y. Prognostic significance of the postoperative level and recovery rate of serum albumin in patients with curatively resected pancreatic ductal adenocarcinoma. Mol Clin Oncol 2019;11:270-8. [PMID: 31384459 DOI: 10.3892/mco.2019.1883] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]